News from map pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 02, 2013, 17:15 ET

MAP Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the 31st Annual J.P. Morgan Healthcare Conference on...

Nov 21, 2012, 17:00 ET

MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX®

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that its New Drug Application (NDA) resubmission for LEVADEX® orally inhaled migraine...

Nov 08, 2012, 16:30 ET

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences: Lazard Capital...

Nov 01, 2012, 16:10 ET

MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the third quarter ended September 30, 2012. The net loss...

Oct 16, 2012, 07:00 ET

MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has resubmitted its New Drug Application (NDA) to the United States Food...

Aug 29, 2012, 17:00 ET

MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriter's Option to Purchase Additional Shares of Common Stock

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the underwriter of its recent public offering of common stock fully exercised...

Aug 09, 2012, 07:00 ET

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present at the following investor conferences: Canaccord Genuity...

Aug 01, 2012, 09:05 ET

MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of an underwritten public offering of 3,880,598 shares of its common...

Jul 31, 2012, 16:02 ET

MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it intends to offer and sell shares of its common stock in an underwritten...

Jul 24, 2012, 07:00 ET

MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the second quarter ended June 30, 2012. The net loss for the...

Jun 25, 2012, 07:00 ET

MAP Pharmaceuticals Provides Update Following Meeting with FDA for LEVADEX® (dihydroergotamine) New Drug Application

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company completed an End-of-Review meeting with the United States Food and Drug...

Jun 21, 2012, 16:05 ET

MAP Pharmaceuticals to Present Data on LEVADEX® at the 54th Annual Scientific Meeting of the American Headache Society

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will present data on LEVADEX® (formerly MAP0004), an orally inhaled...

May 04, 2012, 07:00 ET

MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the first quarter ended March 31, 2012. The net loss for the first...

May 01, 2012, 07:00 ET

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in the following investor conferences in May...

Apr 12, 2012, 16:05 ET

MAP Pharmaceuticals Provides Update on LEVADEX® Program

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on LEVADEX®, the Company's investigational orally inhaled drug for the...

Mar 29, 2012, 07:00 ET

MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2011. The net...

Mar 26, 2012, 19:23 ET

MAP Pharmaceuticals Receives Complete Response Letter from FDA for LEVADEX® (dihydroergotamine) NDA

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Food and Drug Administration (FDA) has issued a Complete...

Feb 23, 2012, 07:00 ET

MAP Pharmaceuticals Issued Additional U.S. Patent for Methods of Achieving Rapid Treatment of Migraine Based Upon Pharmacokinetic Profile

MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Patent and Trademark Office (USPTO) issued to the Company U.S....

Feb 08, 2012, 07:00 ET

MAP Pharmaceuticals to Present at Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Feb. 8, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company will participate in...

Jan 17, 2012, 07:00 ET

MAP Pharmaceuticals Appoints W. James O'Shea to Board of Directors

 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of W. James O'Shea to its Board of Directors. Mr. O'Shea brings to...